The effects on bone metabolism in patients using hydroxychloroquine

Completed

• Conditions: osteoporosis; 10005959

• Registration Number: NL-OMON42271
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 81

Inclusion Criteria

Age > 18 years
Patients with pSS, sarcoidosis, RA or SLE who start with HCQ

Exclusion Criteria

Other underlying auto-immune disease
Use of medications against osteoporosis (e.g. bisphosphonates)
Severe vitamin D deficiency (serum level < 20 nmol/L)
Untreated hyperthyroidism
Untreated hyperparathyroidism
Use of corticosteroids (prednisone equivalent of > 7.5 mg for > 3 months in the last year)
Multiple myeloma
Mastocytosis

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main outcome of this study is to evaluate the changes in beta-CTX due to<br /><br>HCQ treatment. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To evaluate the change in serum PINP and BAP in patients who start with HCQ<br /><br>treatment </p><br>